171 related articles for article (PubMed ID: 27591953)
1. Clinical testing of an inactivated influenza A/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam.
Phan TL; Ho VT; Vu MH; Nguyen TN; Duong HT; Holt R; Wahid R; Donnelly J; Flores J
Vaccine; 2016 Oct; 34(45):5449-5456. PubMed ID: 27591953
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults.
Song JY; Choi MJ; Noh JY; Choi WS; Cheong HJ; Wie SH; Lee JS; Woo GJ; Lee SH; Kim WJ
Hum Vaccin Immunother; 2017 May; 13(5):1190-1197. PubMed ID: 27996363
[TBL] [Abstract][Full Text] [Related]
4. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1).
Duong TN; Thiem VD; Anh DD; Cuong NP; Thang TC; Huong VM; Chien VC; Phuong NTL; Montomoli E; Holt R; Scorza FB; Flores J; Tewari T
Vaccine; 2020 Feb; 38(6):1541-1550. PubMed ID: 31812464
[TBL] [Abstract][Full Text] [Related]
6. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults.
Anh DD; Thiem VD; Anh NTH; Huong VM; Nga NT; Thang TC; Thai DH; Chien VC; Holt R; Wahid R; Flores J; Berlanda Scorza F; Taylor DN
Vaccine; 2016 Oct; 34(45):5457-5462. PubMed ID: 27567493
[TBL] [Abstract][Full Text] [Related]
7. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of inactivated monovalent influenza A/H1N1 vaccine candidate manufactured in Vietnam.
Thang HV; Huong VM; Victor JC; Van CB; Nga NT; Be LV; Cuong NP; Tsvetnitsky V; Neuzil KM; Power M; Flores J
Vaccine; 2018 Nov; 36(46):6918-6925. PubMed ID: 30337172
[TBL] [Abstract][Full Text] [Related]
9. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
Lin J; Zhang J; Dong X; Fang H; Chen J; Su N; Gao Q; Zhang Z; Liu Y; Wang Z; Yang M; Sun R; Li C; Lin S; Ji M; Liu Y; Wang X; Wood J; Feng Z; Wang Y; Yin W
Lancet; 2006 Sep; 368(9540):991-7. PubMed ID: 16980114
[TBL] [Abstract][Full Text] [Related]
11. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
Precioso AR; Miraglia JL; Campos LM; Goulart AC; Timenetsky Mdo C; Cardoso MR; Luna E; Mondini G; Guedes Jda S; Raw I
Vaccine; 2011 Nov; 29(48):8974-81. PubMed ID: 21945258
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
[TBL] [Abstract][Full Text] [Related]
15. An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.
Sansyzbay AR; Erofeeva MK; Khairullin BM; Sandybayev NT; Kydyrbayev ZK; Mamadaliyev SM; Kassenov MM; Sergeeva MV; Romanova JR; Krivitskaya VZ; Kiselev OI; Stukova MA
Clin Vaccine Immunol; 2013 Aug; 20(8):1314-9. PubMed ID: 23803900
[TBL] [Abstract][Full Text] [Related]
16. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
Bernstein DI; Edwards KM; Dekker CL; Belshe R; Talbot HK; Graham IL; Noah DL; He F; Hill H
J Infect Dis; 2008 Mar; 197(5):667-75. PubMed ID: 18260764
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial.
Wu UI; Hsieh SM; Lee WS; Wang NC; Kung HC; Ou TY; Chen FL; Lin TY; Chen YC; Chang SC
Vaccine; 2017 Jul; 35(33):4099-4104. PubMed ID: 28668573
[TBL] [Abstract][Full Text] [Related]
19. A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam.
Lan PT; Toan NT; Thang HA; Thang TC; Be LV; Thai DH; Huong VM; Nga NT; Tang Y; Holt R; Francesco BS; Flores J; Tewari T
Hum Vaccin Immunother; 2019; 15(12):2933-2939. PubMed ID: 31070986
[No Abstract] [Full Text] [Related]
20. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
